The Impact of Memantine on Electroconvulsive Therapy (ECT): Will it Improve Response and Protect Against Cognitive Problems?
NCT ID: NCT00988663
Last Updated: 2017-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2009-11-30
2009-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608
Donepezil Memory Preservation Post ECT
NCT02331771
Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients
NCT00200538
The Effect of Memantine on Brain Structure and Chemistry in Alzheimer's Disease Patients
NCT00255086
Evaluation of Memantine Versus Placebo on Ischemic Stroke Outcome
NCT02535611
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Memantine arm
Patient receiving ECT and Memantine
memantine
patient will receive 5mg daily for 7day then 10 mgm daily
placebo
25 patients receiving ECT will will receive placebo
memantine
patient will receive 5mg daily for 7day then 10 mgm daily
Placebo
will give placebo that looks like memantine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
memantine
patient will receive 5mg daily for 7day then 10 mgm daily
Placebo
will give placebo that looks like memantine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Mental retardation
* Seizure disorder
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jerrry L Lewis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jerrry L Lewis
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerry L Lewis, MD
Role: PRINCIPAL_INVESTIGATOR
University of Iowa Hospitals and Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Iowa hosptitals and clinic
Iowa City, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Memantine ECT trial
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.